Beisol Pharma Meerle: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
Beisol Pharma Meerle
Largest movements
- Receivables within one year -€8,553
down €8,553 (-27.8%), from €30,720 to €22,167
of which Trade receivables: -€10,240
- Trade debts -€10,500
no longer reported in 2026 (was €10,500)
- Profit (loss) carried forward +€10,336
up €10,336 (+11.5%), from -€89,540 to -€79,204
- Other debts -€7,518
down €7,518 (-3.8%), from €198,187 to €190,669
- Gross operating margin -€1,995
down €1,995 (-15.6%), from €12,799 to €10,804
- Purchases and services +€1,995
up €1,995 (+26.0%), from €7,681 to €9,676
From the 2025 result to the 2026 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2025 and 2026 balance sheets and the 2026 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2025 | 2026 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €137,475 | €128,773 | -€8,702 | -6.3% |
| Current assets | 29/58 | €137,475 | €128,773 | -€8,702 | -6.3% |
| Stocks and contracts in progress | 3 | €106,575 | €106,575 | = | 0.0% |
| Stocks | 30/36 | €106,575 | €106,575 | = | 0.0% |
| Amounts receivable within one year | 40/41 | €30,720 | €22,167 | -€8,553 | -27.8% |
| Trade receivables | 40 | €30,720 | €20,480 | -€10,240 | -33.3% |
| Other amounts receivable | 41 | - | €1,687 | +€1,687 | |
| Cash at bank and in hand | 54/58 | €180 | €31 | -€149 | -82.8% |
| Total equity and liabilities | 10/49 | €137,475 | €128,773 | -€8,702 | -6.3% |
| Equity | 10/15 | -€72,232 | -€61,896 | +€10,336 | +14.3% |
| Contributions | 10/11 | €6,200 | €6,200 | = | 0.0% |
| Capital | 10 | €6,200 | €6,200 | = | 0.0% |
| Issued capital | 100 | €18,600 | €18,600 | = | 0.0% |
| Uncalled capital | 101 | €12,400 | €12,400 | = | 0.0% |
| Reserves | 13 | €11,108 | €11,108 | = | 0.0% |
| Non-distributable reserves | 130/1 | €555 | €555 | = | 0.0% |
| Legal reserve | 130 | €555 | €555 | = | 0.0% |
| Distributable reserves | 133 | €10,553 | €10,553 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€89,540 | -€79,204 | +€10,336 | +11.5% |
| Amounts payable | 17/49 | €209,707 | €190,669 | -€19,038 | -9.1% |
| Amounts payable within one year | 42/48 | €209,707 | €190,669 | -€19,038 | -9.1% |
| Trade debts | 44 | €10,500 | - | -€10,500 | |
| Suppliers | 440/4 | €10,500 | - | -€10,500 | |
| Taxes, remuneration and social security | 45 | €1,020 | - | -€1,020 | |
| Taxes | 450/3 | €1,020 | - | -€1,020 | |
| Other amounts payable | 47/48 | €198,187 | €190,669 | -€7,518 | -3.8% |
| Turnover | 70 | €20,480 | €20,480 | = | 0.0% |
| Goods, raw materials, services and sundry goods | 60/61 | €7,681 | €9,676 | +€1,995 | +26.0% |
| Other operating charges | 640/8 | €387 | €411 | +€24 | +6.2% |
| Gross operating margin | 9900 | €12,799 | €10,804 | -€1,995 | -15.6% |
| Operating profit (loss) | 9901 | €12,412 | €10,393 | -€2,019 | -16.3% |
| Financial charges | 65/66B | €30 | €56 | +€26 | +86.7% |
| Recurring financial charges | 65 | €30 | €56 | +€26 | +86.7% |
| Profit (loss) for the period before taxes | 9903 | €12,382 | €10,337 | -€2,045 | -16.5% |
| Profit (loss) for the period | 9904 | €12,382 | €10,337 | -€2,045 | -16.5% |
| Profit (loss) for the period to be appropriated | 9905 | €12,382 | €10,337 | -€2,045 | -16.5% |
Source: filed annual accounts (NBB), financial years ended 31 March 2025 and 31 March 2026. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 29 October 2026 via checked.be.